TapewireFind a company

person · Reporting owner

ROSEN TERRY J

Disclosed activity across 2 companies

Tapewire entity
36787
SEC CIK
0001182473

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Arcus Biosciences, Inc.RCUS · Entity 4104Director · Chief Executive OfficerJanuary 23, 2026January 27, 2026
IDEAYA Biosciences, Inc.IDYA · Entity 4069DirectorJune 16, 2026June 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Arcus Biosciences, Inc.

Report date January 23, 2026 · Filed January 27, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect2,236,409 Reported balance After 2026-01-23 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-01-23 · Grant · Acquired 79,000 · Balance 2,236,409

F1: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company.

F2: Includes the unvested portion of the Reporting Person's RSU grants.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.13 · Expires 2036-01-22Direct315,000 Reported balance After 2026-01-23 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-01-23 · Grant · Acquired 315,000 · Balance 315,000

F3: The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company.

F2: Includes the unvested portion of the Reporting Person's RSU grants.

F3: The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company.

IDEAYA Biosciences, Inc.

Report date June 16, 2026 · Filed June 18, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.57 · Expires 2036-06-16Direct20,000 Reported balance After 2026-06-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-16 · Grant · Acquired 20,000 · Balance 20,000

F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 24, 2019 Filed Dec 20, 2019 00:09 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 GrantStock Option (right to buy) · Derivative 1,250 $0.00 Strike: $9.15 $0.00
Disclosure

SEC source: 0001567619-19-023460 · doc1.xml · derivative · entry 1

ROSEN TERRY J · CIK 0001182473 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,250

Underlying: Common Stock · 1,250 shares

Expires 2029-09-23

F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date.

Read SEC document
June 06, 2019 Filed Jun 7, 2019 18:03 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 PurchaseCommon Stock 2,380 $7.95 $18,928.14
Disclosure

SEC source: 0001209191-19-035453 · doc4.xml · nonDerivative · entry 2

ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By The Rosen Family Trust

Disclosed balance after: 3,023,139

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.88 to $8.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
June 05, 2019 Filed Jun 7, 2019 18:03 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 PurchaseCommon Stock 19,358 $7.93 $153,416.02
Disclosure

SEC source: 0001209191-19-035453 · doc4.xml · nonDerivative · entry 1

ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By The Rosen Family Trust

Disclosed balance after: 3,020,759

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.73 to $8.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
June 04, 2019 Filed Jun 5, 2019 14:35 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 PurchaseCommon Stock 25,770 $7.75 $199,825.73
Disclosure

SEC source: 0001209191-19-034622 · doc4.xml · nonDerivative · entry 2

ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By The RosenFamily Trust

Disclosed balance after: 3,001,401

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.42 to $8.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
June 03, 2019 Filed Jun 5, 2019 14:35 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 PurchaseCommon Stock 15,770 $8.16 $128,749.43
Disclosure

SEC source: 0001209191-19-034622 · doc4.xml · nonDerivative · entry 1

ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By The Rosen Family Trust

Disclosed balance after: 2,975,631

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.90 to $8.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
January 16, 2019 Filed Jan 18, 2019 17:59 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantStock Option (right to buy) · Derivative 200,000 $0.00 Strike: $10.36 $0.00
Disclosure

SEC source: 0001209191-19-004477 · doc4.xml · derivative · entry 1

ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2029-01-15

F1 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after January 16, 2019, subject to the Reporting Person's continued service to the Company.

Read SEC document
August 28, 2018 Filed Aug 29, 2018 17:25 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 PurchaseCommon Stock 10,650 $15.48 $164,844.96
Disclosure

SEC source: 0001209191-18-048775 · doc4.xml · nonDerivative · entry 3

ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 3,959,861

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.04 to $15.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
August 27, 2018 Filed Aug 29, 2018 17:25 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 PurchaseCommon Stock 800 $14.92 $11,937.04
Disclosure

SEC source: 0001209191-18-048775 · doc4.xml · nonDerivative · entry 2

ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 3,949,211

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.89 to $14.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
August 27, 2018 Filed Aug 29, 2018 17:25 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 PurchaseCommon Stock 7,157 $14.48 $103,649.11
Disclosure

SEC source: 0001209191-18-048775 · doc4.xml · nonDerivative · entry 1

ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 3,948,411

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
August 24, 2018 Filed Aug 24, 2018 21:55 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 PurchaseCommon Stock 4,954 $13.40 $66,363.29
Disclosure

SEC source: 0001209191-18-048417 · doc4.xml · nonDerivative · entry 3

ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 3,941,254

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.20 to $13.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
August 23, 2018 Filed Aug 24, 2018 21:55 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 PurchaseCommon Stock 2,133 $13.50 $28,800.19
Disclosure

SEC source: 0001209191-18-048417 · doc4.xml · nonDerivative · entry 2

ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 3,936,300

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.27 to $13.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
August 22, 2018 Filed Aug 24, 2018 21:55 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 PurchaseCommon Stock 2,202 $13.52 $29,776.55
Disclosure

SEC source: 0001209191-18-048417 · doc4.xml · nonDerivative · entry 1

ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 3,934,167

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.36 to $13.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
August 21, 2018 Filed Aug 21, 2018 23:27 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 PurchaseCommon Stock 2,790 $13.20 $36,828.00
Disclosure

SEC source: 0001209191-18-047851 · doc4.xml · nonDerivative · entry 3

ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 3,931,965

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.12 to $13.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
August 20, 2018 Filed Aug 21, 2018 23:27 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 PurchaseCommon Stock 1,301 $13.21 $17,186.21
Disclosure

SEC source: 0001209191-18-047851 · doc4.xml · nonDerivative · entry 2

ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 3,929,175

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.07 to $13.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
August 17, 2018 Filed Aug 21, 2018 23:27 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 PurchaseCommon Stock 4,800 $13.27 $63,712.80
Disclosure

SEC source: 0001209191-18-047851 · doc4.xml · nonDerivative · entry 1

ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 3,927,874

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.20 to $13.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
August 16, 2018 Filed Aug 16, 2018 21:30 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 PurchaseCommon Stock 8,932 $12.95 $115,648.86
Disclosure

SEC source: 0001209191-18-047133 · doc4.xml · nonDerivative · entry 3

ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 3,923,074

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.75 to $13.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
August 15, 2018 Filed Aug 16, 2018 21:30 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 PurchaseCommon Stock 13,300 $12.57 $167,239.52
Disclosure

SEC source: 0001209191-18-047133 · doc4.xml · nonDerivative · entry 2

ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 3,914,142

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.33 to $13.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
August 14, 2018 Filed Aug 16, 2018 21:30 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 PurchaseCommon Stock 6,169 $12.36 $76,238.97
Disclosure

SEC source: 0001209191-18-047133 · doc4.xml · nonDerivative · entry 1

ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 3,900,842

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
August 13, 2018 Filed Aug 13, 2018 21:38 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 PurchaseCommon Stock 3,279 $11.75 $38,534.15
Disclosure

SEC source: 0001209191-18-046475 · doc4.xml · nonDerivative · entry 3

ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 3,894,673

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.54 to $11.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
August 10, 2018 Filed Aug 13, 2018 21:38 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 PurchaseCommon Stock 2,550 $11.94 $30,450.57
Disclosure

SEC source: 0001209191-18-046475 · doc4.xml · nonDerivative · entry 2

ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 3,891,394

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.86 to $12.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
August 09, 2018 Filed Aug 13, 2018 21:38 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 PurchaseCommon Stock 4,100 $11.92 $48,869.13
Disclosure

SEC source: 0001209191-18-046475 · doc4.xml · nonDerivative · entry 1

ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 3,888,844

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.41 to $12.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
March 19, 2018 Filed Mar 19, 2018 21:23 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 ConversionSeries C Convertible Preferred Stock · Derivative 82,966 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-18-007985 · doc4.xml · derivative · entry 6

ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 0

Underlying: Common Stock · 82,966 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

F2 · price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

F2 · derivative.exercise_date: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

F2 · derivative.expiration_date: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

F5 · derivative.underlying_shares: Represents shares of Series C Convertible Preferred Stock indirectly owned by the Reporting Person as a result of a trust's purchase of such shares from the Issuer on November 6, 2017 for $11.6915 per share.

Read SEC document
March 19, 2018 Filed Mar 19, 2018 21:23 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 ConversionSeries B Convertible Preferred Stock · Derivative 125,012 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-18-007985 · doc4.xml · derivative · entry 5

ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 0

Underlying: Common Stock · 125,012 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

F2 · price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

F2 · derivative.exercise_date: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

F2 · derivative.expiration_date: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

Read SEC document
March 19, 2018 Filed Mar 19, 2018 21:23 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 ConversionSeries A Convertible Preferred Stock · Derivative 2,267,676 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-18-007985 · doc4.xml · derivative · entry 4

ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 0

Underlying: Common Stock · 2,267,676 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

F2 · price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

F2 · derivative.exercise_date: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

F2 · derivative.expiration_date: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

Read SEC document
March 19, 2018 Filed Mar 19, 2018 21:23 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 PurchaseCommon Stock 66,666 $15.00 $999,990.00
Disclosure

SEC source: 0000899243-18-007985 · doc4.xml · nonDerivative · entry 2

ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 3,884,744

F3 · shares: Represents shares purchased in the Issuer's initial public offering.

Read SEC document
March 19, 2018 Filed Mar 19, 2018 21:23 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 ConversionCommon Stock 2,475,654 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-18-007985 · doc4.xml · nonDerivative · entry 1

ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 3,818,078

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The total represents shares received upon conversion of shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock.

F2 · price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.